MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 18.08.2022
CureVac N.V. Betriebsaufwand 2011-2026 | CVAC
Betriebsaufwand Jährlich CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 88.9 M | 68 M | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 88.9 M | 68 M | 78.4 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
127 M | $ 82.0 | 3.13 % | $ 1.58 B | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.58 | -1.53 % | $ 16.2 M | USA |
 |
Beam Therapeutics
BEAM
|
479 M | $ 29.29 | 0.93 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
5.39 B | $ 176.18 | 0.77 % | $ 25.7 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 116.77 | 0.53 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.26 | -3.55 % | $ 7.84 B |  Australia |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.1 | -1.2 % | $ 8.92 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 10.15 | -5.45 % | $ 668 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Cerus Corporation
CERS
|
135 M | $ 2.32 | -1.69 % | $ 428 M | USA |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Coherus BioSciences
CHRS
|
231 M | $ 2.33 | 5.19 % | $ 219 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 223.95 | 0.67 % | $ 5 B |  Danmark |
 |
Cellectis S.A.
CLLS
|
109 M | $ 3.99 | -1.72 % | $ 116 M |  France |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.66 | 1.9 % | $ 1.52 B | Britain |
 |
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 69.12 | 5.4 % | $ 9.25 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
190 M | $ 24.58 | 1.57 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
49.3 M | $ 1.62 | -0.31 % | $ 77.2 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
DBV Technologies S.A.
DBVT
|
121 M | $ 22.96 | -3.41 % | $ 2.23 B | France |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
539 M | $ 14.11 | 1.15 % | $ 4.36 B | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |